Menu
Recruiting NCT05561842

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)

Observational Breast Cancer Breast Cancer Female

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: mHealth US-breast biopsy.
Who it may be relevant to
Registry conditions: Breast Cancer, Breast Cancer Female. Basic parameters: from 18 years · Female.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States, Nigeria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria

Overview

The purpose of this study is to train Nigerian radiologists to perform ultrasound-guided breast biopsies. Researchers will use mHealth devices to create a sustainable and practical way of training radiologists in Nigeria to perform and clinically implement US-guided breast biopsies into their practice.

Interventions

  • Procedure mHealth US-breast biopsy
    During this study, women will undergo an US-guided breast biopsy by a radiologist instead of what is typically performed in Nigerian hospitals, which is either a blind biopsy or surgical excision. US-guided breast biopsy is the standard of care in the United States of America because the accuracy is better than blind biopsy and equal to surgical excision.

Primary outcome measures

  • Number of successful US-guided breast biopsy [Time frame: 1 year]

Eligibility criteria

Inclusion criteria

  • Age 18 and older female.
  • Breast ultrasound demonstrating a solid mass that is suspicious for cancer, which would typically undergo either a blind biopsy or surgical excision at the Nigerian hospital where the patient is seeking diagnosis.

Exclusion criteria

  • Participants unwilling to sign consent.
  • Participants under the age of 18.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Nigeria · 7 centers
  • Lagos University Teaching Hospital — Idi-Araba
  • Olabisis Onabanjo University Teaching Hospital (Data Collection Only) — Sagamu
  • Federal Medical Centre Owo (Data Collection Only) — Owo
  • University College Hospital (Data Collection Only) — Ibadan
  • University Of Nigeria Teaching Hospital (UNTH) Ituku-Ozalla Enugu — Enugu
  • Obafemi Awolowo University Teaching Hospitals Complex (Data Collection Only) — Ile-Ife
  • University of Ilorin Teaching Hospitals — Ilorin
United States · 1 center
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) — New York

Identifiers

NCT: NCT05561842 · 21-325

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗